A single-center study assessing SARS-CoV-2 vaccine-specific humoral and cellular responses in patients treated with ocrelizumab compared with healthy controls
Latest Information Update: 30 Sep 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 30 Sep 2021 New trial record
- 23 Sep 2021 Results published in the JAMA Neurology